Alzheimer disease. Alzheimer disease
Conditions
Interventions
Intervention 1: one group of Patients is treated randomly with quetiapine alone, 12.5 mgr in night and rise to 25 to 50 mg according to patient condition. Intervention 2: one group of Patients is trea
Treatment - Drugs
one group of Patients is treated randomly with quetiapine alone, 12.5 mgr in night and rise to 25 to 50 mg according to patient condition
one group of Patients is treated randomly with Risperidone alone, 0.5 mgr in night and rise to 1 to 2 mg daily according to patient condition
one group of Patients randomly received Quetiapine 12.5 mg or higher dose ,combined with a monthly 1000 mcgr. vitamin B12
one group of patients randomly received Risperidone 0.5 mg or higher dose combined with 1000 mcgr vitamin B12 per month
Sponsors
Rafsanjan University of Medical Siences
Eligibility
Sex/Gender
All
Age
65 Years to 85 Years
Inclusion criteria
Inclusion criteria: Alzheimer diagnosis in elderly patients is carried out on basis of clinical interviews; DSM IV diagnosis criteria; medical history; clinical examinations; MRI and brain CT scan results and the mini mental state examination score; Patients who have mini mental score above than are studied; patient with Brief Psychiatric Rating Scale score 30-70. Exclusion criteria Patients who were taking anti-psychotic medication; has schizophrenia symptoms; preliminary psychotic disorders; delirium; psychoses followed by drug or medication take; Other medical background disorders like B12 deficiency and hypothyroidism; Patients needed to be hospitalized; Patients posed to suicide commitment risk; Other causes of dementia like brain tumors; strokes; normal pressure hydrocephalus; Underlying medical conditions; that may cause behavioral or psychotic symptoms or delirium such as infection, medications with anticholinergic effects; corticosteroid use; or neurological insults is the first step in the decision-making process for treatment. In addition, the patients were discarded from the procedure if they need further medical intervention and other drugs according to their health status or families’ remark
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: before treatment , 2 weeks and 8 weeks after treatment. Method of measurement: Visual Analogue Scale for pain Questionnaire.;Psychiatric symptoms. Timepoint: before treatment , 2 weeks and 8 weeks after treatment. Method of measurement: Breif Psychiatric Rating Scale Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient progress and treatment response. Timepoint: 2 weeks and 8 weeks after treatment. Method of measurement: Clinical Global Impressions scale Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contact?Alireza Vakilian
Rafsanjan University Of Medical Sciences
Outcome results
None listed